English

TELA Bio, Inc.

EDGAR

TELA Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2025: about Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 80.28M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 69.3M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

19.3 million Unit_Standard_USD_WndfyxI7b02RuujOESqQrw

2026 Q2 · Unit_Standard_USD_WndfyxI7b02RuujOESqQrw

Exact inputs and evidence

Revenue: 19291000 Unit_Standard_USD_WndfyxI7b02RuujOESqQrw Source

Operating margin

-48.12%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -9283000 Unit_Standard_USD_WndfyxI7b02RuujOESqQrw Source
Revenue: 19291000 Unit_Standard_USD_WndfyxI7b02RuujOESqQrw Source

Cash and cash equivalents: 30.4 million Unit_Standard_USD_WndfyxI7b02RuujOESqQrw 2026-06-30 Source
Exact value

30424000 Unit_Standard_USD_WndfyxI7b02RuujOESqQrw
Long-term debt including current maturities: 41.4 million Unit_Standard_USD_MKhzpOs-v0ecslrBh6u7OQ 2025-06-30 Source
Exact value

41384000 Unit_Standard_USD_MKhzpOs-v0ecslrBh6u7OQ
Shares outstanding: 44.8 million Unit_Standard_shares_p8mjIRCCoUS34eUaLModSQ 2026-06-30 Source
Exact value

44833942 Unit_Standard_shares_p8mjIRCCoUS34eUaLModSQ

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
Long-term debt including current maturities: Multiple units; comparison withheld· newest 2024-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+15.8%

Prior period

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 69.3 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 80.28 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

80275000 − 69300000 = 10975000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ

69300000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
80275000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Year-over-year change in Revenue: 10975000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 80275000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1823019 Filing: 000110465926034507 Input fundies:Revenue: 69300000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1824073 Filing: 000110465926034507
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 990,000

Prior period

−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 37.84 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 38.83 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-38831000 − -37841000 = -990000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ

-37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Year-over-year change in Net income: -990000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1491835 Filing: 000110465926034507 Input fundies:NetIncome: -37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1437181 Filing: 000110465926034507
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 13.38 million

Prior period

−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 41.6 million

2024-01-01 – 2024-12-31
Current period

−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 28.22 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-28219000 − -41595000 = 13376000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ

-41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Year-over-year change in Operating cash flow: 13376000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1576235 Filing: 000110465926034507 Input fundies:OperatingCashFlow: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1577378 Filing: 000110465926034507
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-54.7%

Prior period

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 989,000

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 448,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

448000 − 989000 = -541000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ

989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Year-over-year change in Capital expenditure: -541000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1582396 Filing: 000110465926034507 Input fundies:CapitalExpenditure: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1583463 Filing: 000110465926034507
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 80.28 million 100% of revenue
Cost of revenue Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 25.93 million 32% of revenue
Operating expenses Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 88.1 million 110% of revenue
Operating income −Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 33.76 million −42% of revenue
Tax, interest and other Derived Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 5.08 million 6.3% of revenue
Net income −Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 38.83 million −48% of revenue

Cash

Operating cash flow −Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 28.22 million −35% of revenue
Capital expenditure Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 448,000 0.6% of revenue
Free cash flow Derived −Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 28.67 million −36% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 175% of revenue.
2024 Operating loss: operating costs were 149% of revenue.
2025 Operating loss: operating costs were 142% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	58453000	102528000 Derived	-44075000	2589000 Derived	-46664000	-41468000 Derived	Source 2023-01-01 – 2023-12-31: 58453000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Revenue Open source 2023-01-01 – 2023-12-31: -44075000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -46664000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Net Income Open source 2023-01-01 – 2023-12-31: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	69300000	103415000 Derived	-34115000	3726000 Derived	-37841000	-42584000 Derived	Source 2024-01-01 – 2024-12-31: 69300000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Revenue Open source 2024-01-01 – 2024-12-31: -34115000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Net Income Open source 2024-01-01 – 2024-12-31: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	80275000	114030000 Derived	-33755000	5076000 Derived	-38831000	-28667000 Derived	Source 2025-01-01 – 2025-12-31: 80275000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Revenue Open source 2025-01-01 – 2025-12-31: -33755000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Net Income Open source 2025-01-01 – 2025-12-31: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 80.3M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ)	Source evidence
20232023-12-31	Revenue	58453000	Revenue: 58453000 Open source
20242024-12-31	Revenue	69300000	Revenue: 69300000 Open source
20252025-12-31	Revenue	80275000	Revenue: 80275000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

15.8% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 58453000 Open source
20242024-12-31	Year over year	18.6%	Revenue: 69300000 Open source Revenue: 58453000 Open source
20252025-12-31	Year over year	15.8%	Revenue: 80275000 Open source Revenue: 69300000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -42% 2025

Net margin -48.4% 2025

Free cash flow margin -35.7% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-75.4%	Operating Income: -44075000 Open source Revenue: 58453000 Open source
20242024-12-31	Operating margin	-49.2%	Operating Income: -34115000 Open source Revenue: 69300000 Open source
20252025-12-31	Operating margin	-42%	Operating Income: -33755000 Open source Revenue: 80275000 Open source
20232023-12-31	Net margin	-79.8%	Net Income: -46664000 Open source Revenue: 58453000 Open source
20242024-12-31	Net margin	-54.6%	Net Income: -37841000 Open source Revenue: 69300000 Open source
20252025-12-31	Net margin	-48.4%	Net Income: -38831000 Open source Revenue: 80275000 Open source
20232023-12-31	Free cash flow margin	-70.9%	Revenue: 58453000 Open source Operating Cash Flow: -40857000 Open source Capital Expenditure: 611000 Open source
20242024-12-31	Free cash flow margin	-61.4%	Revenue: 69300000 Open source Operating Cash Flow: -41595000 Open source Capital Expenditure: 989000 Open source
20252025-12-31	Free cash flow margin	-35.7%	Revenue: 80275000 Open source Operating Cash Flow: -28219000 Open source Capital Expenditure: 448000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ -28.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ)	Source evidence
20232023-12-31	Operating cash flow	-40857000	Operating Cash Flow: -40857000 Open source
20242024-12-31	Operating cash flow	-41595000	Operating Cash Flow: -41595000 Open source
20252025-12-31	Operating cash flow	-28219000	Operating Cash Flow: -28219000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ -28.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ)	Source evidence
20232023-12-31	Free cash flow	-41468000	Operating Cash Flow: -40857000 Open source Capital Expenditure: 611000 Open source
20242024-12-31	Free cash flow	-42584000	Operating Cash Flow: -41595000 Open source Capital Expenditure: 989000 Open source
20252025-12-31	Free cash flow	-28667000	Operating Cash Flow: -28219000 Open source Capital Expenditure: 448000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 46.66 million Exact value Exact value: -46664000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2023-01-01 – 2023-12-31: -46664000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Net Income Open source Share or cite Citation for Net Income · TELA Bio, Inc. · 2023-12-31 TELA Bio, Inc. (edgar:1561921) Net Income: -46664000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:NetIncome: -46664000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1393590 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 40.86 million Exact value Exact value: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2023-01-01 – 2023-12-31: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TELA Bio, Inc. · 2023-12-31 TELA Bio, Inc. (edgar:1561921) Operating Cash Flow: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:OperatingCashFlow: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1578522 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 611,000 Exact value Exact value: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2023-01-01 – 2023-12-31: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TELA Bio, Inc. · 2023-12-31 TELA Bio, Inc. (edgar:1561921) Capital Expenditure: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:CapitalExpenditure: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1584531 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 41.47 million Calculation and evidence -40857000 − 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Exact free cash flow: -41468000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2023-01-01 – 2023-12-31: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TELA Bio, Inc. · 2023-12-31 TELA Bio, Inc. (edgar:1561921) Free cash flow: -41468000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -40857000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1578522 Filing: 000110465926034507 Input fundies:CapitalExpenditure: 611000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1584531 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 37.84 million Exact value Exact value: -37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2024-01-01 – 2024-12-31: -37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Net Income Open source Share or cite Citation for Net Income · TELA Bio, Inc. · 2024-12-31 TELA Bio, Inc. (edgar:1561921) Net Income: -37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:NetIncome: -37841000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1437181 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 41.6 million Exact value Exact value: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2024-01-01 – 2024-12-31: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TELA Bio, Inc. · 2024-12-31 TELA Bio, Inc. (edgar:1561921) Operating Cash Flow: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:OperatingCashFlow: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1577378 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 989,000 Exact value Exact value: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2024-01-01 – 2024-12-31: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TELA Bio, Inc. · 2024-12-31 TELA Bio, Inc. (edgar:1561921) Capital Expenditure: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:CapitalExpenditure: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1583463 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 42.58 million Calculation and evidence -41595000 − 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Exact free cash flow: -42584000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2024-01-01 – 2024-12-31: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TELA Bio, Inc. · 2024-12-31 TELA Bio, Inc. (edgar:1561921) Free cash flow: -42584000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41595000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1577378 Filing: 000110465926034507 Input fundies:CapitalExpenditure: 989000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1583463 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 38.83 million Exact value Exact value: -38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2025-01-01 – 2025-12-31: -38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Net Income Open source Share or cite Citation for Net Income · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Net Income: -38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:NetIncome: -38831000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1491835 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 28.22 million Exact value Exact value: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2025-01-01 – 2025-12-31: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Operating Cash Flow: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:OperatingCashFlow: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1576235 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 448,000 Exact value Exact value: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2025-01-01 – 2025-12-31: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Capital Expenditure: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ&dimensions= Input fundies:CapitalExpenditure: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1582396 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 28.67 million Calculation and evidence -28219000 − 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Exact free cash flow: -28667000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ 2025-01-01 – 2025-12-31: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TELA Bio, Inc. · 2025-12-31 TELA Bio, Inc. (edgar:1561921) Free cash flow: -28667000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T08:45:20Z Snapshot: e69b23e39c965d2ec43c9dba0546fa5a69327620d565da68fc997eb78af0c7bd Dimensions: Consolidated View: https://fundies.io/companies/edgar/1561921?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28219000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1576235 Filing: 000110465926034507 Input fundies:CapitalExpenditure: 448000 Unit_Standard_USD_2dVcgf73kUaXAjhBMfkMoQ (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1561921/000110465926034507/tela-20251231x10k.htm#1582396 Filing: 000110465926034507 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

36 filings · 3,865 latest values · 3,865 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001561921, 1561921, TELA, edgar:1561921

Also known as TELA Bio, Inc.

TELA Bio, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation